Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Cervical Cancer Clinical Trials

A listing of Cervical Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (207) clinical trials

Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast Ovarian Endometrial or Cervical Cancer

OBJECTIVES: - Evaluate tumor response and toxicity induced by fluorouracil and doxorubicin HCl liposome combined with mild systemic hyperthermia in patients with metastatic breast, ovarian, endometrial, or cervical cancer. OUTLINE: This is a time-escalation study of systemic hyperthermia. Patients receive fluorouracil IV continuously over 24 hours on days 1-5 and ...

Phase

Tisotumab Vedotin (HuMax -TF-ADC) Safety Study in Patients With Solid Tumors

The study is conducted in two parts. The dose escalation portion of the trial subjects are enrolled into cohorts at increasing dose levels of tisotumab vedotin (HuMax-TF-ADC) in 28 day treatment cycles. In the Cohort Expansion part of the trial, will further explore the recommended phase 2 dose of tisotumab ...

Phase

Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)

Fourteen women with a biopsy-confirmed CIN3 diagnosis will be enrolled. The participants will receive 500mg of curcumin orally twice daily for 12 weeks. Colposcopies will be performed at the participants' baseline, 6 week, and 12 week visits. Two biopsies will be performed at the baseline and 12 week visit, and ...

Phase N/A

Localization of Point A in Cervical Cancer

Radiation therapy (RT), with a relevant integration of external beam radiotherapy (EBRT) and intracavitary brachytherapy (ICBT), is an important part in the treatment of cervical cancer. Even though concurrent chemoradiation therapy (CCRT) improves the control of locoregional recurrence and distant metastasis for locally advanced disease, the role of RT remains ...

Phase N/A

Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB Stage II Stage III or Stage IVA Cervical Cancer

OBJECTIVES: Primary - Determine the response rate, in terms of clinical or radiologic response at 12 weeks after completion of study therapy, in patients with stage IB2-IVA cervical cancer treated with neoadjuvant chemotherapy comprising dose-dense paclitaxel and carboplatin followed by radical chemoradiotherapy comprising concurrent cisplatin and radiotherapy. Secondary - Determine ...

Phase

Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical Vaginal and Vulvar Dysplasia and Cancer

Anal cancer as well as cervical, vaginal, and vulvar cancer can be caused by an infection called human papillomavirus (HPV). Researchers do not know how often anal cancer and dysplasia occur together with cervical, vaginal or vulvar high-grade dysplasia, or invasive squamous cell carcinoma. All of these diseases are caused ...

Phase N/A

ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer

Indication Treatment of subjects with advanced (FIGO stage IVB) or recurrent cervical cancer, prior radiochemotherapy or neo-adjuvant chemotherapy is allowed. Study design: This is a phase II randomized, double blind and placebo controlled trial evaluating the efficacy of Nintedanib/placebo in combination with the standard carboplatin and paclitaxel followed by Nintedanib/placebo ...

Phase

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Background We have constructed a single retroviral vector that contains both alpha and beta chains of a T cell receptor (TCR) that recognizes the HLA-A 01 restricted MAGE-A3 tumor antigen, which can be used to mediate genetic transfer of this TCR with high efficiency. In co-cultures with HLA-A 01 and ...

Phase

NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma

PRIMARY OBJECTIVES: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced ...

Phase

Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms

By enrolling patients with unresectable Uterine Cervical Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Uterine Cervical Neoplasms.

Phase